Peakadilly, a predictive protein biomarkers company, has been awarded a grant extension from the Flanders government to accelerate the development of its protein biomarker discovery platform
This grant will support Peakadilly in expanding its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products.
The company has already secured a series of granted patents and revenue-generating projects with pharma.
The grant was awarded by the Flanders government through IWT-Flanders, the Institute for the Promotion of Innovation by Science and Technology in Flanders.
IWT-Flanders is an organisation providing financial support to Flemish companies, research institutes and individuals executing industrial research and development projects, to stimulate and support their innovation.
Commenting on the grant, Koen Kas, founder and CSO said: "Together with our income from R+D partnerships this grant has helped us to build Peakadilly and to attract one of the biggest rounds of European series A VC financing, which we closed last month.
"Moving forward, our goal is to deliver proof of concept for the development of the first high throughput mass spectrometry based serum protein profiling assay as we progress in the development of next generation molecular diagnostics".
Peakadilly has implemented an innovative protein biomarker discovery technology that will transform the potential of protein biomarkers in molecular diagnostics and drug discovery and development.
The company's protein biomarker discovery operation is based on its proprietary Masstermind technology and includes the development of novel blood sample depletion technologies and innovative chromatographic approaches, as well as novel mass spectrometry techniques and data interpretation methods.
